We are giving life to new classes of medicine to change the lives of patients with devastating diseases
We are giving life to new classes of medicine to change the lives of patients with devastating diseases
Clinical success is measured as the probability of transition success from Phase 1 to Phase 3. The cumulative percentages are calculated by multiplying the individual phase percentages. Industry average data measures the probability of clinical trial success of therapeutics by calculating the number of programs progressing to the next phase vs. the number progressing and suspended (Phase 1=52%, Phase 2=29%, Phase 3=58%). BIO, PharmaIntelligence, QLS (2021) Clinical Development Success Rates 2011 – 2020. This report did not include therapeutics regulated as devices. PureTech aggregate percentages including all therapeutic candidates advanced through at least Phase 1 by PureTech or its Founded Entities from 2009 onward, using the aforementioned calculation method based on the following individual phase percentages, Phase 1 (75%), Phase 2 (83%), Phase 3 (75%), last reviewed on June 30, 2023; Phase 2 and Phase 3 percentages include some therapeutic candidates where a previous trial was not conducted by PureTech or its Founded Entities because it was not required by regulatory authority.